EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
Overall EXAS gets a fundamental rating of 4 out of 10. We evaluated EXAS against 588 industry peers in the Biotechnology industry. EXAS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, EXAS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
EXAS had negative earnings in the past year.
EXAS had a positive operating cash flow in the past year.
EXAS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of EXAS (-3.15%) is better than 92.12% of its industry peers.
EXAS's Return On Equity of -6.49% is amongst the best of the industry. EXAS outperforms 92.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.15% | ||
| ROE | -6.49% | ||
| ROIC | N/A |
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EXAS has a better Gross Margin (73.83%) than 85.10% of its industry peers.
EXAS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EXAS has more shares outstanding
The number of shares outstanding for EXAS has been increased compared to 5 years ago.
Compared to 1 year ago, EXAS has a worse debt to assets ratio.
2.2 Solvency
EXAS has an Altman-Z score of 1.72. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
EXAS has a better Altman-Z score (1.72) than 69.86% of its industry peers.
The Debt to FCF ratio of EXAS is 75.84, which is on the high side as it means it would take EXAS, 75.84 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of EXAS (75.84) is better than 93.66% of its industry peers.
A Debt/Equity ratio of 0.74 indicates that EXAS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.74, EXAS is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 75.84 | ||
| Altman-Z | 1.72 |
ROIC/WACCN/A
WACC7.8%
2.3 Liquidity
A Current Ratio of 2.32 indicates that EXAS has no problem at all paying its short term obligations.
EXAS's Current ratio of 2.32 is on the low side compared to the rest of the industry. EXAS is outperformed by 75.00% of its industry peers.
EXAS has a Quick Ratio of 2.07. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of EXAS (2.07) is worse than 75.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.07 |
3. Growth
3.1 Past
EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.76%, which is quite impressive.
Looking at the last year, EXAS shows a quite strong growth in Revenue. The Revenue has grown by 19.93% in the last year.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 40.63% on average per year.
EPS 1Y (TTM)66.76%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q62.5%
Revenue 1Y (TTM)19.93%
Revenue growth 3Y18.79%
Revenue growth 5Y40.63%
Revenue growth Q2Q16.98%
3.2 Future
EXAS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.87% yearly.
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.79% yearly.
EPS Next Y25.16%
EPS Next 2Y41.98%
EPS Next 3Y40.85%
EPS Next 5Y33.87%
Revenue Next Year13.73%
Revenue Next 2Y13.89%
Revenue Next 3Y13.48%
Revenue Next 5Y12.79%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EXAS. In the last year negative earnings were reported.
Also next year EXAS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, EXAS is valued cheaply inside the industry as 94.01% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 365.27 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 40.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.98%
EPS Next 3Y40.85%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXACT SCIENCES CORP
NASDAQ:EXAS (4/24/2024, 5:03:41 PM)
Premarket: 64 +0.76 (+1.2%)63.24
-0.29 (-0.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.48B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.15% | ||
| ROE | -6.49% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 73.83% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.32 | ||
| Quick Ratio | 2.07 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)66.76%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.16%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)19.93%
Revenue growth 3Y18.79%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y